This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Li, L. Articles by Li, X. Search for Related Content PubMed PubMed Citation Articles by Li, L. Articles by Li, X. Social Bookmarking                   What's this?

Neuroprotective Effects of Brain-Derived Neurotrophic Factor (BDNF) on Hearing in Experimental Pneumococcal Meningitis

Department of Pediatric Neurology the First People's Hospital of Yunnan Province, Kunming, hxyd_zjdx{at}sohu.com., Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Quan-Xiang Shui, BC

Department of Neurology Affiliated Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Xianzhen Li, BC

Department of Pediatrics the First People's Hospital of Yunnan Province, Kunming, China

Bacterial meningitis is still one of the most common causes of acquired profound sensorineural deafness in children despite antibiotic treatment. We investigated the neuroprotective effects of brain-derived neurotrophic factor on hearing function in experimental bacterial meningitis. We implanted stainless steel tubes into both cerebral ventricles of Sprague-Dawley rats aged 21 days. Bacterial meningitis was induced by inoculating a strain of serotype III Streptococcus pneumoniae into the cisterna magna. Six micrograms per day of brain-derived neurotrophic factor (groups 1 and 3) or albumin (groups 2 and 4) was injected into the cerebral ventricles 24 hours after or before infection, respectively, for a duration of 7 days. Additionally, all rats received antibiotic subcutaneous treatment starting 24 hours after infection for 7 days. Brainstem auditory evoked potentials were recorded 24 hours before and 24 hours after infection and after 7 days of treatment with brain-derived neurotrophic factor or placebo and antibiotics, respectively, to determine hearing threshold. Our results showed that the hearing thresholds of animals in each group increased significantly 24 hours after infection compared with the results recorded 24 hours before infection (P < .01). After 7 days of treatment with brain-derived neurotrophic factor, brainstem auditory evoked potential responses recurred in 16 ears when stimulated at 75 dB hearing level in groups 1 and 3. Their hearing thresholds significantly decreased compared with the control group 2 (P < .05) and group 4 (P < .01). However, 13 of 14 ears absent brainstem auditory evoked potential responses could still not be identified at 75 dB hearing level in control groups 2 and 4. The improvement of the hearing thresholds in group 3 (treated before infection) was greater than that of group 1 (treated after infection) (P < .05), but there was no significant difference found between the control groups before and after infection (P > .05). Our study supports the hypothesis that the administration of exogenous brain-derived neurotrophic factor can be effective in preventing or treating hearing loss following bacterial meningitis. ( J Child Neurol 2005;20:51—56).

Journal of Child Neurology, Vol. 20, No. 1, 51-56 (2005)
DOI: 10.1177/08830738050200010801


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?